Tarlatamab (Imdelltra) is a new type of immunotherapy approved for people with small-cell lung cancer whose disease has ...

Researchers visualized ALK fusion proteins in real time. They showed that ALK inhibitors reshape flexible protein regions to ...

INDIANAPOLIS, Ind. (Ivanhoe Newswire) --- For people battling a certain type of lung cancer, there’s good news. A new targeted therapy is significantly improving lung cancer patient outcomes. The drug ...

A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...

On January 12, NP-G2-044 (Prilukae), a novel oral fascin inhibitor earned ODD for the treatment of pancreatic cancer. This designation covers the use of the agent as monotherapy and in combination ...

T cell engagers, including Imdelltra, show promise in small cell lung cancer, outperforming chemotherapy in trials and changing the standard of care. Antibody-drug conjugates like I-DXd and ABBV-706 ...

WASHINGTON, Jan. 15, 2026 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, and Rising Tide Foundation for Clinical Cancer Research (RTFCCR) ...

Lung cancer is the leading cause of cancer deaths in the U.S., according to the American Cancer Society. For people battling a certain type of lung cancer, there’s good news. A new targeted therapy is ...

Researchers recently tried an experiment: Gather people who had the same kind of lung cancer and put them on the same type of treatments to fire up their immune systems. The only difference was that ...

INDIANAPOLIS, Ind. – Lung cancer is the leading cause of cancer deaths in the U.S., according to the American Cancer Society. For people battling a certain type of lung cancer, there’s good news. A ...